Following the successful completion of the NHS national pilot in April 2025, the highly anticipated first results assessing CYP2C19 genetic testing to guide clopidogrel use in ischaemic stroke and TIA ...

The optimism is not unfounded. In specific, well-defined clinical scenarios, polygenic scores are beginning to demonstrate some tangible utility. For cardiovascular disease, MI-GENES, a 10-year follow ...

The UK is a recognised powerhouse for genomic science and medicine. Genomics England’s 100,000 Genomes Project is the largest sequencing project of its kind in the world and, building on these ...

The UK government has launched a new alliance to sequence the genomes of SARS-CoV-2, the virus responsible for the current COVID-19 pandemic. Backed by a £20 million investment, the COVID-19 Genomics ...

Inter-CeBIL is the International Collaborative Biomedical and Innovation Law program involving the law faculties at Copenhagen, Cambridge, Harvard and select other partners. PHG Foundation is ...

These plans have been a long time in the making. The intention to produce a strategy ‘to ensure the UK is able to offer a predictive, preventative and personalised health and care service for people ...

Widely regarded as a founder of cell free DNA (cfDNA) technology, Professor Dennis Lo is now pioneering investigation into the emerging science of fragmentomics. If you were at were at our recent ...

The term ‘mainstreaming’ was first used in 2003 by the Secretary of State for Health in the context of the genetics white paper Our Inheritance, Our Future when he argued that genomics must move from ...

The rapid development, approval and roll out of multiple vaccines against SARS-CoV-2, the virus that causes COVID-19, is an impressive achievement for science and healthcare. The virus genome was ...

Until the coronavirus pandemic took hold, it seemed that at least every other headline about healthcare innovations was related to machine learning or other forms of artificial intelligence (AI) – ...

A recent consultation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) indicates a welcome new direction for public and patient involvement (PPI). The MHRA proposed new five-year ...

Cost-utility studies provide critical information for the costs and benefits of using any new test, typically building on existing public health and screening programmes, within a defined population.